-
Pharmaceutical companies are robbing people by "involution"!
Time of Update: 2022-05-02
The continuous enhancement of the competitiveness of local pharmaceutical companies has formed a strong attraction for overseas R&D talents; pharmaceutical companies, including traditional pharmac
-
The Health and Health Commission issued a document: Restrict the use of imported medical consumables!
Time of Update: 2022-05-02
Improve the recruitment mechanism and promote the substitution of domestic consumables The Guangdong Provincial Medical Insurance Bureau stated that in the future, it will establish and improve the coordination mechanism for medical insurance payment standards and centralized procurement of medical consumables.
-
How many hurdles does the internationalization of Chinese pharmaceutical companies need to pass?
Time of Update: 2022-05-02
The measures include supporting enterprises to carry out simultaneous registration of innovative drugs at home and abroad, and conducting global multi-center clinical research for developed country markets.
Domestic Me-better innovative drug companies also need to consider the intellectual property rights of their products when they internationalize .
-
CStone Receives New $2 Billion Varieties for 4 Consecutive Years
Time of Update: 2022-05-02
On February 17, CStone announced that the new drug application for pratinib has been accepted in Taiwan, China, the drug is mainly used for the treatment of locally advanced or metastatic non-small c
-
9 pharmaceutical and biological companies issued repurchase plans, most of which exceeded 100 million yuan
Time of Update: 2022-05-02
Tigermed announced on the evening of February 14 that the company plans to use its own funds or self-raised funds to repurchase some of the company's A shares through centralized bidding transactions, with a repurchase amount of not less than 250 million yuan and not more than 50 million yuan.
-
25 listed pharmaceutical and biological companies disclosed their 2021 performance reports
Time of Update: 2022-05-02
From the perspective of revenue, 4 of the 25 listed pharmaceutical and biological companies have a revenue of over 10 billion yuan, namely Kelun Pharmaceutical, Sinopharm Hyundai, Zhifei Bio, and WuXi AppTec .
-
Sinopharm Modern Nifedipine Controlled-Release Tablets and Omeprazole Enteric-Coated Tablets Pass the Consistency Evaluation of Generic Drugs
Time of Update: 2022-05-02
The sales revenue of the company's nifedipine controlled-release tablets in 2020 is approximately RMB 1.
According to the CDE website, the companies that have passed or are deemed to have passed the consistency evaluation of nifedipine controlled-release tablets include Beijing Honglin Pharmaceutical Co.
-
Huadong Medicine's wholly-owned subsidiary signed an equity investment agreement with Heidelberg Pharma
Time of Update: 2022-05-02
On February 28, Huadong Medicine announced that its wholly-owned subsidiary signed an equity investment agreement with Heidelberg Pharma in Germany and obtained an exclusive license agreement for the company's products .
, a wholly-owned subsidiary of the company, has reached an exclusive product license agreement with Heidelberg Pharma.
-
Ten billion biopharmaceutical equipment + consumables market attracts pharmaceutical machine giants to accelerate their layout
Time of Update: 2022-05-02
On February 22, the domestic pharmaceutical machine giant Chutian Technology mentioned in the newly released investor relations activity record sheet, "Global innovative drugs and biological drugs are booming, and there is a great demand for high-level, high-quality medical equipment .
-
Henan Enlargement Recruitment: Collecting 6 varieties of flow standards, purchasing more than 200 million
Time of Update: 2022-05-02
Previously (October 29, 2021), the Henan Provincial Bureau issued the "Notice on Matters Concerning the Reference Monitoring Scope of Alternative Drugs for Centralized Procurement of Varieties in the State and Our Province" (Yu Medical Insurance Office [2021] No.
-
4 domestic pharmaceutical companies released 2021 performance reports, 2 reported good news
Time of Update: 2022-05-02
61% over the same period last year; the net profit attributable to shareholders of the parent company is 171 million yuan, an increase of 77.
Jing Pharmaceutical's 2021 annual performance bulletin shows that during the reporting period, the company achieved operating income of 201 million yuan, a year-on-year increase of 627.
-
The pharmaceutical manufacturing industry will see strong profit growth in 2021, with a year-on-year increase of nearly 80%
Time of Update: 2022-05-02
Among them, the pharmaceutical manufacturing industry will see strong profit growth in 2021, with a year-on-year increase of nearly 80% .
-
In February, the pharmaceutical and biological companies were investigated by institutions, and the number of 3 reception fund companies exceeded 30
Time of Update: 2022-05-02
The record form of investor relations activities disclosed by Changchun Hi-Tech on February 21 shows that 145 institutional investors including Broadway Fund and Bosera Fund investigated the company on February 18.
-
Domestic pharmaceutical companies are attacking class 1 new drugs, and good news in this field continues
Time of Update: 2022-05-02
On February 18, Osaikang announced that the innovative drug ASKG712 injection independently developed by Suzhou Osaikang, a wholly-owned subsidiary, was approved by the State Food and Drug Administration for clinical trials.
-
Kexing Pharmaceutical's 2021 performance: total revenue of 1.285 billion yuan, a year-on-year increase of 5.31%
Time of Update: 2022-05-02
285 billion yuan in 2021, a year-on-year increase of 5.
31%; net profit attributable to owners of the parent company is 90 million yuan, a year-on-year decrease of 35.
45 yuan, a year-on-year decrease of 51.
83%, a year-on-year decrease of 13.
-
Kangchen Pharmaceutical's KC1036 entered Phase Ib/II clinical study for the treatment of advanced digestive system tumors
Time of Update: 2022-05-02
On February 23, Kangchen Pharmaceutical issued an announcement saying that recently, Kangchen Pharmaceutical's "Phase Ib/II clinical study plan to evaluate the efficacy and safety of KC1036 in the treatment of advanced recurrent or metastatic digestive system tumors" was published in the Chinese Academy of Medical Sciences.
-
CDE Publishes Guidelines for Mixing Uniformity and Intermediate Control Dose Uniformity of Chemical Drug Solid Preparations
Time of Update: 2022-05-02
On February 18, the CDE official website issued an announcement stating that in order to guide the research on the mixing uniformity of chemical oral solid preparations and the uniformity of the medi
-
With frequent personnel changes, domestic pharmaceutical companies have ushered in major adjustments
Time of Update: 2022-05-02
For example, on February 23, Guangshengtang announced that the company recently appointed George Zhang (Zhang Yuhua) as the company's innovative drug holding subsidiary Fujian Guangsheng Zhonglin Biotechnology Co.
-
This anticoagulant drug market with sales of over 100 million has added another entrant!
Time of Update: 2022-05-02
The industry pointed out that for the generic drug of apixaban, a blockbuster product, the country is already in a situation of competition for hegemony, and it is uncertain which pharmaceutical company can win in the domestic anticoagulant market in the future .
-
Jiangxi Provincial Food and Drug Administration issued a notice to further strengthen the production management of Chinese herbal medicine pieces
Time of Update: 2022-05-02
In order to further improve and strengthen our province's Fresh Bamboo Lek Chinese herbal medicine pieces, ensure clinical efficacy, prevent product quality risks, and enhance the brand value of Gan-produced Chinese herbal medicine pieces, we are now in accordance with the "Pharmaceutical Administration Law of the People's Republic of China" and the "Measures for the Supervision and Administration of Drug Production", etc.
